Introduction
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are essential second messengers regulating multiple signaling pathways in virtually all cell types. 1 Intracellular levels are finely regulated by cyclic nucleotide phosphodiesterases (PDEs), which degrade cAMP and cGMP by hydrolysis of both cAMP and cGMP to the corresponding nucleoside 5 0 monophosphate. 2 PDE10A (MIM: 610652) encodes phosphodiesterase 10A, a dual cAMP-cGMP phosphodiesterase enriched in the medium spiny neurons (MSNs) of the corpus striatum. 3 The underlying pathology of the classic movement disorders Parkinson disease (PD [MIM: 168600]) and Huntington disease (HD [MIM: 143100]) focuses on a loss of dopamine-producing cells in the substantia nigra in PD and striatal MSNs in HD. 4, 5 This results in dysregulated cortical striatal-thalamic connections, contributing to both motor and cognitive symptoms. 6, 7 PDE10A modulates G-protein-coupled signaling, including that due to activation of dopamine receptors D1 and D2, by degrading cyclic nucleotides and in animal models regulates the basal ganglia circuitry. 8, 9 These observations have stimulated extensive research into PDE10A as a therapeutic target, 10 despite little physiological data in humans. By a combination of homozygosity mapping and whole-exome sequencing (WES), we identified biallelic missense variants in two families affected by a hyperkinetic movement disorder. Cellular modeling of the variants revealed lower PDE10A levels in cells expressing the mutant than in cells expressing the wild-type (WT). Crucially, this recapitulated our observations in one of the individuals, who showed a marked loss of striatal PDE01A by positron-emission-tomography (PET) scanning. In a knock-in (KI) mouse model, we recapitulated the loss of striatal PDE10A, and the mice also displayed a motor phenotype. This suggests that there is strong back-translation of the human gene-phenotype findings in individuals with biallelic PDE10A mutations.
Subjects and Methods

Subject Evaluation
The families provided signed informed consent to participate in studies approved by the Leeds East research ethics committee (07/H1306/113; family 1) and by the ethics committee of the Oulu University Hospital (EETTMK 51/2008; family 2). Two individuals underwent video recordings for further documentation of their movement disorders (Movies S1 and S2).
Two families affected by a distinct movement disorder were independently ascertained and investigated ( Figure 1A ). Individual IV:2 (family 1) underwent a PET scan with [ 11 C]IMA107, a selective PDE10A PET radiotracer, allowing a robust quantification of PDE10A levels.
Neuroimaging Evaluation
Image Acquisition PET and MRI scans were performed at Imanova. After providing written informed consent, participants were instructed to refrain . Levels of WT and mutant PDE10A were measured in HEK293 cells by immunoblotting using a specific PDE10A polyclonal antibody (Rbg426v2). The PDE10A band is highlighted with an arrowhead. The amount of mutant proteins was lower than that of the WT. Quantification of PDE10A in transfected HEK293 cells was normalized to GAPDH levels. Experiments were replicated four times with four technical replicates per experiment. Data are presented as a group mean 5 SEM. ***p < 0.001. from caffeine, tobacco, and alcohol for at least 12 hr before scanning. Healthy control individuals were recruited as part of an ongoing study. 11 Subjects were positioned supine, and head position was maintained as previously described. 11 All participants were scanned on a Siemens Biograph HI-REZ 6 PET-CT scanner after the injection of an intravenous bolus of~250 
Genetic Analysis
In view of the consanguinity in both families, genetic analysis was performed under a recessive model. In family 1, we performed a genome-wide homozygosity scan by using the Affymetrix Human SNP Array 6.0 on DNA from four affected and two unaffected individuals. Genotype data were analyzed with AutoSNPa and IBDfinder software. 13, 14 Two affected individuals from family 2 were investigated by chromosomal microarray on DNA extracted from fibroblasts with a 50-mer oligochip (HumanCytoSNP-12 v.2.1 BeadChip, Illumina). Analysis was performed with both GenomeStudio (hg19) and KaryoStudio (hg18) programs (Illumina).
WES
Analyses for Family 1 Alignment and Variant Calling. Target capture was performed with the Agilent SureSelect Human All Exon v.4 exome enrichment kit according to the manufacturer's standard protocol. Sequencing of 150-bp paired-end reads was performed with an Illumina MiSeq. Reads were aligned to GRCh37 with Novoalign (Novocraft Technologies) and processed with the Genome Analysis Toolkit (GATK) and Picard (see Web Resources) for realignment of short indels and removal of duplicate reads. Depth of coverage of the consensus coding sequence (CCDS) was assessed with GATK, which showed that >94% of CCDS bases were covered by at least five good-quality reads (minimum Phred-like base quality of 17 and minimum mapping quality of 20). Single-nucleotide variants (SNVs) and indels were called with the GATK UnifiedGenotyper feature. 15, 16 Filtering. Custom Perl scripts were used for removing variants present in dbSNP132 or with a minor allele frequency R 0.1% and for annotating functional consequences. We called variants in the autozygous region only with a minimum Phred-like genotype quality of 30 and selected for indels within coding regions, non-synonymous SNVs, and splice-site variants. Variants present in the 1000 Genomes dataset (November 2011), the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) Exome Variant Server, and another 2,500 ethnically matched in-house exomes were also removed. Analyses for Family 2 Target capture was performed with the Agilent SureSelect Human All Exon v.4.1 according to the manufacturer's standard protocol. Sequencing was performed on the Illumina GAIIx instrument, generating 100 bp paired-end reads. In brief, the Burrows-Wheeler Aligner (v.0.5.9) was used to align raw reads against the reference human genome (NCBI Genome build GRCh37). 17 Local realignment around indels and coverage assessment were performed with GATK, 16 was used to target a loxP-flanked neomycin cassette into intron 4 of the Pde10a locus along with the TAT:TGT codon mutation in exon 4 of a murine bacterial artificial clone (BAC) (RP23-67C3, Invitrogen). Again via Red/ET recombineering, we cloned approximately 11 kb of the Pde10a locus, including the newly introduced neomycin cassette along with the p.Tyr97Cys genetic modification, from the BAC into a pUC57 plasmid to generate the final sequence-confirmed targeting vector. The linearized PDE10A p.Tyr97Cys targeting vector was electroporated into murine Bruce4 embryonic stem (ES) cells (from Colin Stewart, National Cancer Institute), which were grown according to standard procedures previously described. 21 After G418 selec- Generating KI Mice Carrying PDE10A p.Tyr97Cys
Targeted ES cells carrying the PDE10A p.Tyr97Cys variant with a normal 40XY karyotype (Coriell Institute for Medical Research) were microinjected into BALB/c blastocyst-stage embryos (Charles River Laboratories) according to standard procedures previously described. 22 Resulting chimeric males were mated to EIIa-Cre transgenic females for the generation of offspring heterozygous for PDE10A p.Tyr97Cys in the germline and free of the neomycin selection cassette. Offspring from these and all subsequent matings were genotyped by qPCR analysis at Transnetyx; offspring with homozygous KI of PDE10A p.Tyr97Cys along with WT controls were then generated from heterozygous mating pairs. The Pfizer Institutional Animal Care and Use Committee reviewed and approved the animal use in these studies. The animal care and use program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
Behavioral Phenotyping of KI Mice Carrying p.Tyr97Cys
Upon arrival at the animal facility, separate cohorts of young (4-5 weeks) and adult (7-10 weeks) WT/WT (WT), WT/KI (HET), and KI/KI (KI) male mice (n ¼ 7-13 per genotype) were individually housed in standard ventilated caging on a 12/12 hr light/ dark cycle (lights on at 6:00 a.m.) and were provided with food and water ad libitum. Mice were acclimatized for a minimum of 5 days prior to testing. Mice were subjected to a battery of behavioral tests during the light cycle with a minimum 2 day inter-test interval (ITI). Mice from the young cohort were maintained in the facility at the conclusion of initial phenotyping until they reached 24-25 weeks of age, at which time they were re-evaluated as aged mice. The phenotyping battery consisted of the SHIRPA protocol 23 and then the following tests in order.
Rotarod
Balance and coordination were evaluated in test mice with an automated accelerating rotarod (Rotamex; Columbus Instruments). The rotarod consisted of four lanes separated by a visual barrier with a rotating spindle (3.0 cm diameter) elevated 44.5 cm from the floor. Infrared beams placed at the level of the spindle detected the presence or absence of the animal on the spindle. Mice were placed on the rotarod at 4 RPM, which was accelerated at a rate of 1 RPM per 8 s throughout a 5 min trial period. Mice were subjected to five consecutive trials separated by a 30 5 5 min ITI. Trials ended at the conclusion of the 5 min trial period or when the mouse fell from the rod. Latency to fall (s) was recorded and analyzed by a two-way repeated-measures ANOVA (genotype 3 trial) with GraphPad Prism v.5.0 and Bonferroni post hoc tests as appropriate.
Open-Field Activity VersaMax chambers for monitoring animal activity (AccuScan Instruments) were used for assessing alterations in general exploratory behavior. Chambers were housed in a testing room with environmental conditions similar to those of the housing room (~400 lux and 60-70 dB background noise 
Immunoblotting
Mouse striatal tissue or HEK293 cells were lysed in RIPA buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS supplemented with protease and phosphatase inhibitor cocktails) and homogenized by brief sonication. Equal amounts of protein were separated in a reducing 4%-12% Tris-Glycine gel (Invitrogen) and blotted onto a nitrocellulose membrane (Hybond-ECL, GE). Protein levels were determined by fluorescent or ECl-based immunoblotting followed by densitometric analysis (Li-Cor-Odyssey, ImageJ). The following antibodies were used: mouse-anti-PDE10A-24F3.F11, 24 rabbit-anti-PDE10A-426v2, 25 mouse-anti-GAPDH-MAB374 (Millipore), goatanti-Rabbit-IRDye680 (Li-Cor), goat-anti-Mouse-IRDye800 (LiCor), and donkey-anti-Mouse-HRP (Jackson). Data were analyzed by one-way ANOVA with GraphPad Prism v.5.0.
Results
Clinical Characterization of Families
Family 1 is a consanguineous UK family of Pakistani origin ( Figure 1A , left). All affected individuals presented in childhood (mean age of 3 months) with axial hypotonia and a generalized hyperkinetic movement disorder. This was characterized by dyskinesia of the limbs and trunk. At times, the hyperkinetic movements had a jerky quality, and intermittent chorea and ballismus were also present. Facial involvement was evident with orolingual dyskinesia, drooling, and dysarthria. The severity of the hyperkinesis varies considerably within the family, and the oldest individual is the least affected. Cognitive performance is preserved, and all affected individuals graduated from high school. Family 2 is from northern Finland ( Figure 1A, right) . Two affected boys were born to healthy first-cousin parents. Both boys show mild cognitive delay and severe axial hypotonia. From early infancy, they presented with a generalized hyperkinetic movement disorder characterized by dyskinesia affecting all four limbs and the trunk and face (Movies S1 and S2). Expressive language was not evident until 7 years of age, and both individuals have persistent dysarthria.
IV:2 is more severely affected; he has had focal epilepsy since 3.5 years of age and feeds via a gastrostomy tube. Further clinical details can be found in Table S1 .
In both families, array comparative genomic hybridization, muscle biopsy, and, crucially, brain MRIs in individuals IV:2, V:2, and V:3 from family 1 and both of the affected individuals from family 2 were normal. Further details are provided in the Supplemental Note.
Genetic Analyses Reveal Missense Mutations in
PDE10A
In family 1, genome-wide SNP analysis revealed a single 2.6 Mb region of concordant homozygosity on 6q26. WES revealed one potentially pathogenic variant within the homozygous region: c.320A>G (p.Tyr107Cys) in exon 4 of PDE10A (GenBank: NM_001130690.2) ( Figure 1B) . In family 2, there were 16 common autozygous regions, the three largest of which clustered on 6q26. WES revealed a single potentially deleterious mutation within the homozygous segments: c.346G>C (p.Ala116Pro), also in exon 4 of PDE10A ( Figure 1B) . Neither variant was present in dbSNP, 1000 Genomes, the NHLBI ESP, or our in-house exome databases. Both individual variants are fully conserved back to Danio rerio ( Figure 1B ), lie within a region of very high conservation, and are predicted to be deleterious. 26 Sanger sequencing confirmed the presence of the variants and that they segregate with the phenotype in the families.
PDE10A Levels Are Decreased in an Individual with the p.Tyr107Cys Variant
Given that there are now well-characterized PET ligands for PDE10A, we wanted to understand the impact of the mutations on PDE10A levels in the human brain. Because of ethical considerations, we were able to study only individual IV:2 from family 1 in this manner. PDE10A PET signal was robustly lower in this individual than in healthy control individuals ( Figure 1C) , and quantitative analysis revealed a 70% reduction in PDE10A in all basal ganglia regions ( Figure 1C and Figure S1 ). An accompanying structural MRI showed that this loss of PDE10A signal was not due to loss of striatal volume (see Figure S2 ).
Effect of PDE10A Mutations on PDE10A Levels in HEK293 Cells
To evaluate the functional consequence of the PDE10A mutations, we expressed WT and mutant PDE10A (c.320A>G
and c.346G>C) in HEK293 cells. PDE10A levels were investigated by immunoblotting using validated antibodies (see Figure S3) . A significant decrease in PDE10A levels was associated with both mutations (Figure 1D ), consistent with the human PET study above. Figure S4 ). SHIRPA phenotyping of the HET and KI mice did not reveal any behavioral phenotypes. 23 We therefore investigated locomotor activity in young (4-5 weeks of age), adult (7-10 weeks of age), and old animals (24-25 weeks of age). Data for adult mice are shown in Figures 2A-2C , and data for young and old mice are presented in Figure S5 . KI mice showed significantly less total distance traveled ( Figure 2A and Figure S5 , left) and rearing behavior ( Figure 2B and Figure S5 , middle) than did age-matched HET and WT controls. Relative to age-matched HET and WT controls, KI mice also demonstrated a reduced ability to maintain their balance on an accelerating rotarod ( Figure  2C and Figure S5 , right). In a DWB assay, relative to both HET and WT littermate controls, KI mice demonstrated statistically significant increases in forepaw bearing weight, whereas hindpaw weights were reduced ( Figure S6) . Together, these data show that KI mice display motor abnormalities.
p.Tyr97Cys KI Mice Have Reduced Levels of PDE10A in the Striatum Consistent with the PET data on human PDE10A and the protein studies in HEK293 cells, KI mice showed lower striatal protein levels than did age-matched WT (p < 0.001) and HET animals (p < 0.001; Figures 2D and 2E ). Striatal tissue from KI mice showed lower levels of PDE10A activity than did that of age-matched WT (p < 0.001) and HET animals (p < 0.01; Figure 2F ). Inhibition of PDE10A is known to lead to an increase in levels of phosphorylated CREB (pCREB). After administration of the potent, selective PDE10A inhibitor MP-10, WT and HET mice showed 400% more (p < 0.001) striatal pCREB than did vehicletreated mice. No such increase in pCREB was observed in the KI mice, confirming that the biallelic PDE10A variant reduces downstream pCREB signaling ( Figure 2G ).
Discussion
We have described eight individuals from two families affected by an early-onset hyperkinetic movement disorder associated with mutations in PDE10A. Expression of the mutant variants of human PDE10A in HEK293 cells revealed lower levels of both mutant proteins than of the WT. Critically, these observations were reflected in one of the affected individuals, who had a significant loss of striatal PDE10A signal when investigated with a specific PDE10A PET ligand in the absence of abnormalities on MRI. PDE10A levels in striatal tissue lysates from a KI model were also decreased, leading to a reduced ability to Representative immunoblots of striatal protein lysates from adult mice from each genotype (n ¼ 5 for WT, HET, and KI) were analyzed by immunoblotting for levels of PDE10A with a specific polyclonal PDE10A antibody (Rbg426v2). GAPDH was used as a loading control.
(E) Quantification of PDE10A levels in striatal lysates. Data are presented as the group mean 5 SEM. PDE10A levels were normalized to GAPDH levels. Normalized data were analyzed by one-way ANOVA with GraphPad Prism v.5.0. PDE10A levels were measured in the striatum from adult mice of all three genotypes (n ¼ 5 for WT, HET, and KI). Levels of PDE10A p.Tyr97Cys were lower than WT protein levels. *p < 0.05, ***p < 0.001. (F) The PDE10A p.Tyr97Cys variant led to a reduction in enzymatic activity. PDE10A enzyme activity was measured in striatal lysates from adult mice of all three genotypes (n ¼ 5 for WT, HET, and KI). Enzyme activity was measured by means of a scintillation proximity assay modified from an Amersham Biosciences protocol (TRKQ7090). The assay measures levels of 5 0 AMP produced when cAMP is exposed to phosphodiesterase. Data are presented as the group mean 5 SEM and were analyzed by one-way ANOVA with GraphPad Prism v.5.0. KI mice showed a reduction in PDE10A activity. **p < 0.01, ***p < 0.001. (G) The PDE10A p.Tyr97Cys variant led to a reduction in downstream signaling. Downstream PDE10A signaling was measured indirectly by quantifying pCREB levels in striatum from adult mice of all three genotypes (n ¼ 5 for WT, HET, and KI), which had been dosed with either the selective PDE10A inhibitor MP-10 or vehicle. pCREB levels were higher in both WT and HET animals dosed with the PDE10A inhibitor than in vehicle-treated animals. Data are presented as the group mean 5 SEM and were analyzed by a paired t test with GraphPad Prism v.5.0. ***p < 0.001. degrade cyclic nucleotides. In KI mice, downstream signaling by PDE10A was decreased, demonstrated by an absent pCREB response after dosage with a PDE10A inhibitor.
PDE10A is specifically found at high levels in the striatal MSNs, 3 which receive input from the cortex and thalamus.
MSNs can be divided into two cell types: ''direct pathway'' MSNs (dMSNs) express dopamine receptor D1 and project to the globus pallidus internal segment and substantia nigra pars reticulate, whereas ''indirect pathway'' MSNs (iMSNs) express dopamine receptor D2 and project indirectly to the same nuclei via the globus pallidus external segment and subthalamic nuclei. The classic model predicts that dMSN activation promotes movement, whereas iMSN activation leads to inhibition of movement. 6 PDE10A is expressed in both cell types, but pharmacological data indicate that it might regulate them differentially. 27 Pharmacological inhibition of PDE10A is consistent with the preferential activation of the indirect pathway, 27 which should result in hypokinetic symptoms. Both Pde10a-knock-out (KO) mice 8 and the Pde10a-KI mice described here are indeed hypokinetic. However, the affected individuals experience significant hyperkinetic motor symptoms. This is reminiscent of the phenotypes observed in mouse models of HD. Individuals affected by HD experience an initial hyperkinetic phase followed by a hypokinetic phase. 28 However, only some HD models have a hyperkinetic phase, and it is generally short; 29 the lack of recapitulation of motor symptoms between the KI animal and the affected individuals is thus not unprecedented. Pharmacological inhibitors of PDE10A have been shown to reverse a number of phenotypes in HD mouse models. 9 However PDE10A levels are reduced in animal models of HD. 30 Furthermore, recent PET studies have shown that individuals with pathogenic HTT (MIM: 613004) expansions exhibit reduced levels of striatal PDE10A. 31, 32 This correlates with disease severity, although significant decreases in PDE10A have also been seen in asymptomatic individuals carrying pathogenic expansions. 31, 32 The phenotype described here results from loss of PDE10A activity in the striatum, differentiating the effects of selective PDE10A deficiency from those accompanying striatal cell loss. Our observations confirm that PDE10A plays a key role in regulating striato-cortical movement control. Genetic depletion of PDE10A appears to alter cyclic nucleotide signaling in the MSNs in humans and thus result in an activation of motor activity and a hyperkinetic movement disorder. These data accord with the recent observation of activating mutations in adenylyl cyclase 5, ADCY5 (MIM: 600293). 33, 34 The encoded enzyme converts ATP to pyrophosphate and cAMP and is also found at high levels in the striatum. A hyperkinetic movement disorder was reported in affected individuals, whereas cellular modeling of the mutations confirmed an increase in cAMP levels. The variants we report result in a reduced capacity to degrade cAMP in a cellular model. This is recapitulated in the animal model we report. These observations suggest that modulation of cyclic nucleotide levels in the striatum plays a key role in movement control. Our observations, particularly the lack of pCREB response to PDE10A inhibition in our KI mouse model, suggest that the dose of PDE10A inhibitors might need to be modified in conditions characterized by reduced PDE10A levels. The Amaryllis study, a phase II clinical study of a PDE10A inhibitor, is presently underway in HD. The outcome of these trials will further inform the clinical relevance and impact of our observations.
In conclusion, we report a primary loss of PDE10A due to biallelic PDE10A mutations in humans; this results in striatal dysfunction, leading to a hyperkinetic movement disorder. The effects are independent of any other disease process, including evidence of cell loss. These observations confirm a key role for PDE10A in the physiology of movement control and a central role for modulation of striatal cyclic nucleotide levels in this process. They suggest cellular dysfunction rather than cell death as a cause of movement disorders.
Supplemental Data
Supplemental Data include a Supplemental Note, six figures, one table, and two movies and can be found with this article online at http://dx.doi.org/10.1016/j.ajhg.2016.03.015. 
Conflicts of Interest
Supplemental Note: Case Reports
Family 1 is a UK family of Pakistani origin.
IV:2 was the proband. He presented to the department of clinical genetics at age 5 with generalised developmental delay, motor delay had been evident since age 3 months. At age 5 he was noted to be ataxic with a wide based stamping gait and frequent falls. He was unable to manage tandem gait and had a marked intention tremor. On closer examination he had a generalised movement disorder with dyskinesia of all four limbs in all positions. There was also an orofacial dyskinesa. There was no obvious muscle weakness, there was no peripheral neuropathy or sensory deficit. He was markedly dysarthric, without dysphagia, and in fact had good general comprehension. There was no facial weakness and cranial nerve examination was otherwise normal. Tendon reflexes were brisk but plantars were downgoing.
A diagnosis of a generalised dyskinetic movement disorder was made, with little evidence of a cognitive impairment. He was investigated but there was no evidence of acanthocytes in blood. Urinary organic acid analysis was normal, in particular glutarica ciduria was excluded. Serum copper and ceruloplasmin levels were normal. Thyroid function tests and serum lipids were normal. Routine karyotype was also normal.
! ! !
He was further reviewed throughout childhood and adult life. Last review was at age 38, on examination he had a subtle dyskinesia of the arms, hands and fingers which is made worse when he was asked to raise his hands above his head. On walking his gait was reasonable, but he had clear difficulty maintaining progressive gait on heel-toe testing.
Accompanying this difficulty in walking he had subtle but obvious dyskinesia of the fingers. He had a clear orofacial dyskinesia and his speech is slightly dysarthric. Tendon reflexes were brisk but plantars were downgoing and there was no sensory component or neuropathy.
IV:4 was the sister of the proband and presented at age 3 to the Clinical genetics department. She was again felt to have generalised delay from age 3 months but like her brother her manifestations were principally of a motor disturbance. She had the generalised dyskinetic movements of face trunk and limbs seen in her brother. She was dysarthric, but there were no other cranial nerve abnormalities apparent on examination, there was no real evidence of muscle weakness, there was no evidence of a peripheral neuropathy or sensory loss. She also had brisk tendon reflexes and downgoing plantars.
Cognition was normal. Investigations revealed no obvious cause for her deficit. Routine karyotype was normal. She was reassessed throughout childhood and adult life. At her most recent assessment at age 31 findings were stable with no evidence of progression or improvement.
Individuals III:4 and III:5, the parents of IV:2 and IV:4 were examined and neither had any evidence of motor abnormalities. In view of the family structure and the absence of ! ! ! disease in the parents a diagnosis of an autosomal recessive benign chorea was made. At a later date analysis of NKX2-1 was performed in IV:2 but no mutation was identified.
V:1 was the first daughter of IV:2 and his first cousin. She presented in a very similar fashion to her father with delay in motor development first noted at the age of 4 months.
She then presented with repeated falls and unsteady gait at age 3. She was followed up throughout childhood and was most recently seen at age 16 years. She attended a normal school and at her most recent assessment aged 16 was managing well, planning to complete school examinations. The major issue for her in class had always been her dysarthria which was very debilitating. Despite this her symptoms have remained stable She had a similar degree of dysarthria to her sisters and attended the same school.
V:4 was the first male child to the couple. At age 2 months his mother noted abnormal facial movements and very messy feeding when he was weaned. This pattern was very similar to that noted by her in his sister, V:3. He went on to develop a very similar hyperkinetic movement disorder with dyskinesia of all four limbs and trunk. His speech was clearly dysarthric and and at age 2 he was very difficult to understand. His comprehension of speech was age appropriate. He was unable to stand unsupported at that age and had jerky dyskinetic movements of his limbs, which were worse when he was trying to pull himself to stand. He still had truncal ataxia and dyskinetic movements of his face. He had marked orolingual dyskinesia and severe drooling. His clinical signs at that age were very similar to his siblings at similar ages.
In summary all five individuals had a very stable movement disorder, characterised by hyperkinetic dyskinesia and dysarthria, however there was little evidence of a cognitive component. All investigations, including testing for mutations in NKX2-1, the cause of benign hereditary chorea (BCH OMIM 118700) were normal.
Family 2 is of Caucasian origin and has two affected sons who were born at 35-38 weeks (with birth weights of 3550 g and 3890 g) to healthy parents who are the first cousins.
Both male individuals (Individuals 1 and 2) presented with profound axial hypotonia and athetotic movements at four months of age. Brain MRI, EEG, ENMG and muscle biopsy did not show any specific abnormal findings. Mitochondrial respiratory chain enzyme activities of skeletal muscle sample were normal, and there were no deletions in muscle mitochondrial DNA (mtDNA). Sequencing of the mtDNA and nuclear genes encoding mitochondrial twinkle helicase (PEO1) and polymerase gamma (POLG1) were negative.
Furthermore, XNP and HPRT genes were analyzed to exclude ATR-X and Lesch-Nyhan syndromes, but no pathogenic mutations were found. Extensive metabolic investigations including dopamine metabolites and other neurotransmitters in cerebrospinal fluid were unyielding. Motor and speech development of both individuals has been markedly delayed, but there has been no loss of skills. Both individuals suffer from severe dysarthria and they started to express a few words at the age of seven years, but they mainly communicate with picture symbols and sign language. Their understanding of speech has been estimated to be close to normal. They learned to wheel their wheel chairs independently at 7 years of age as well. Individual 1 was also diagnosed with insulindependent autoimmune diabetes at 7 years of age. At the age of 9 years he is able take a Furthermore, due to difficulties in eating a gastrostomy tube was inserted at 2.5 years of age, and he was diagnosed with focal epilepsy at 3.5 years presenting with focal dyscognitive seizures (impairment of consciousness, interruption of ongoing activities, staring,and swallowing). During carbamazepine (CBZ) treatment he has been seizure free except for occassional seizures with similar seizure type related to too low dose of CBZ.
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